The Combination of Cudc-907 and Gilteritinib Shows Promising In Vitro and In Vivo Antileukemic Activity against FLT3-Itd AML

Investigators showed that gilteritinib and CUDC-907, a dual inhibitor of PI3K and histone deacetylases, synergistically induced apoptosis in FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) cell lines and primary patient samples and had striking in vivo efficacy.